Document:

Exhibit 10.8

 

SUBLEASE

 

Effective as of June 8,
2021 (the “Effective Date”), NATIONAL MEDICAL CARE, INC., a Delaware corporation, (“Sublandlord”), and RAPID
MICRO BIOSYSTEMS, INC., a Delaware corporation (“Subtenant”), hereby agree as follows:

 

1.            Overlease.
As used herein, the term “Overlease” shall mean that certain Lease, dated as of June 21, 2019, by and between DUFFY HARTWELL
LLC., a Massachusetts limited liability company, as Landlord thereunder (“Overlandlord”), and Sublandlord, as Tenant thereunder,
pursuant to which Sublandlord leases certain real property consisting of approximately 33,339 rentable square feet at 25 Hartwell Avenue,
Lexington, Massachusetts shown on Exhibit D (the “Premises”). A true, correct and complete copy of the Overlease is attached
as Exhibit F. Capitalized terms not defined herein shall have the meaning ascribed to them in the Overlease.

 

2.            Sublease.
Sublandlord hereby subleases to Subtenant the entire Premises, subject to the terms and conditions hereof. This Sublease is a sublease
under the Overlease and is subject to all of the terms and provisions thereof; provided, however, that if any provisions of this Sublease
conflict with the provisions of the Overlease, the provisions of this Sublease shall govern. This Sublease shall be deemed to contain
all of the same covenants, agreements, conditions, terms and provisions as contained in the Overlease, mutatis mutandis (the necessary
changes being made to reflect the fact that Sublandlord is the Landlord and Subtenant is the Tenant) except to the extent otherwise provided
herein and except that the following provisions of the Overlease shall not apply hereto:

 

		•	Section 1.2 (To the extent inconsistent herewith).

 

		•	Section 2.2.1 (Second sentence only).

 

		•	Section 2.3.

 

		•	Section 2.4.

 

		•	Section 3.2.

 

		•	Sections 6.1 and 6.2.

 

		•	Section 9.2.5.

 

		•	Section 13.5.

 

		•	Section 13.24.

 

		•	Section 13.39.

 

		•	Section 13.40.

 

		•	Exhibit A-1.

 

		•	Exhibit A-2.

 

     

     

    

 

		•	Exhibit C.

 

		•	Exhibit E.

 

3.            Obligations
of Parties. From and after the Commencement Date, Subtenant hereby agrees to perform all of the obligations applicable to the Premises
imposed on Sublandlord as Tenant under the Overlease, subject to Sections 5 and 6 hereof, and except as expressly provided for herein.
From and after the Commencement Date, Sublandlord shall have no obligations or liabilities under this Sublease except as provided in the
following sentence and in the following Sections of this Sublease. Sublandlord hereby agrees:

 

		(a)	to timely pay all rent and other charges due to the Overlandlord under the Overlease;

 

		(b)	to use due diligence and reasonable efforts to cause the Overlandlord to perform the obligations imposed upon the Overlandlord under
the Overlease which are applicable to this Sublease to Subtenant’s reasonable satisfaction. If any breach or default of Overlandlord
under the Overlease has not been resolved after the expiration of thirty (30) days after notice, then provided that Subtenant is not in
default under this Sublease, upon the request of Subtenant Sublandlord, at Subtenant’s expense, shall take such action, including
legal action, as Sublandlord shall reasonably determine upon to enforce Overlandlord’s obligations The foregoing notwithstanding,
if any breach of the Overlease shall entitle Sublandlord to assert claims for an abatement of rent for constructive eviction or otherwise,
then such abatement shall accrue in favor of Subtenant provided that there shall be no abatement of rent hereunder except to the extent
Sublandlord shall receive a corresponding abatement under the Overlease. If Sublandlord shall be entitled to an abatement rent or other
claims arising from fire or other casualty, then Subtenant shall have the same claims;

 

		(c)	not to (i) surrender or terminate the Overlease prior to its scheduled expiration date without the consent of Subtenant as long
as this Sublease is in effect, or (ii) amend or modify the Overlease, the result of which would materially and adversely affect Subtenant’s
rights or obligations under this Sublease or the Premises;

 

		(d)	to comply with all the terms and provisions of the Overlease, except to the extent Subtenant has assumed the same;

 

		(e)	to, promptly following receipt thereof, deliver to Subtenant a copy of any and all notices received by Sublandlord from Master Landlord
which would have any material effect upon the Premises or this Sublease; and

 

		(f)	to pay Overlandlord any administrative fees or other expenses required to be paid to, or for Overlandlord in connection with the submission
of this Sublease for Overlandlord’s consent.

 

This Sublease is subject and subordinate to the
Overlease and shall terminate upon the expiration or earlier termination of the Overlease.

 

     

     

    

 

The liability insurance maintained by Subtenant
pursuant to Section 9.2.1 of the Overlease shall name Sublandlord, Overlandlord and any other parties required by such Section as
additional insureds.

 

For the purpose of Section 13.22 of the Overlease
(Non-Subrogation), references to “Landlord”, “Tenant”, “each party” and the like shall be deemed to
mean Overlandlord, Sublandlord and Subtenant, or each of them, as appropriate.

 

4.            Term;
Delivery of Premises. The term of this Sublease (“Sublease Term”) shall begin on August 1, 2021 (the “Commencement
Date”) and shall expire on June 30, 2029; provided that in no event shall such Commencement Date occur unless and until the
Overlandlord’s Consent has been obtained. The Premises shall be delivered in its current as-is condition and in otherwise good working
order and condition including, but not limited to all HVAC and other mechanical systems, lighting, fans, plumbing, electrical fixtures
and restrooms. After receipt of Overlandlord’s Consent, Subtenant may, at no charge to Subtenant, provided Subtenant shall have
first provided a certificate of the insurance required of it hereunder, enter the Premises for the purpose of preparing the same for its
occupancy from and after the Effective Date, including performing its tenant improvements and installing necessary furniture, fixtures
and equipment. Notwithstanding anything in this sublease or the Overlease to the contrary, in no event shall Subtenant have any obligation
to replace the HVAC unit(s) existing in the Premises as it is Overlandlord’s obligation to make all necessary repairs and replacements
thereto. Subtenant shall pay for any such repairs or replacements charged to the Sublandlord according to the Overlease.

 

5.            Fixed
Rent. Beginning four (4) months after the Commencement Date (the “Rent Commencement Date”), Subtenant shall pay to
Sublandlord Fixed Rent as set forth in Exhibit A hereto (in lieu of the Fixed Rent set forth in the Overlease), payable in advance
on or before the first of each month.

 

6.            Additional
Rent. Beginning on the Commencement Date, Subtenant shall pay the Additional Rent for Taxes and Operating Expenses in accordance with,
and subject to Article 8 of the Overlease. Subtenant shall be entitled to receive any reduction or refund of any Taxes allocable
to the Sublease Term obtained by Landlord and received by Tenant pursuant to Section 8.1.8 of the Overlease.

 

7.            Security
Deposit1. As security for Subtenant’s faithful performance
of its obligations hereunder, Subtenant shall deliver to Sublandlord, upon the execution of this Sublease by Subtenant, a clean, irrevocable
letter of credit in the face amount of $184,000, issued to Sublandlord as the sole beneficiary, substantially in the form of Exhibit C
hereto (the “Letter of Credit”). The Letter of Credit shall have a stated duration of and shall be effective for at least
one (1) year with provision for automatic successive annual one-year extensions during the Term and for sixty (60) days thereafter.
Subtenant shall keep the Letter of Credit in force throughout the Term and for sixty (60) days after the expiration date or the earlier
termination of the Term. Subtenant shall deliver to Sublandlord a renewal Letter of Credit no later than thirty (30) days prior to the
expiration date of any Letter of Credit issued under this Section 7, and, if Subtenant fails to do so, Sublandlord may draw the
entire amount of the expiring Letter of Credit and hold the proceeds in cash as the Security Deposit, as hereinafter provided, but in
that event, Subtenant shall, upon demand, provide Sublandlord with a new Letter of Credit, meeting the requirements of this Sublease
as a security deposit, in lieu of such cash, and upon receipt of such replacement Letter of Credit, Sublandlord shall promptly return
such cash security deposit to Subtenant. The Letter of Credit shall be issued by a commercial bank reasonably satisfactory to and approved
by Sublandlord.

 

 

1 Under review by issuing bank.

 

     

     

    

 

If Subtenant fails to pay Fixed Rent or other charges
due hereunder, or otherwise defaults with respect to any provision of this Sublease beyond any applicable notice and cure periods, Sublandlord
may (but shall have no obligation to) use all or any portion of the Letter of Credit for the payment of any monthly installment of Fixed
Rent or other charge due hereunder, to pay any other sum to which Sublandlord may become obligated by reason of Subtenant’s default,
or to compensate Sublandlord for any loss or damage which Sublandlord may suffer thereby. If Sublandlord so uses or applies all or any
portion of the Letter of Credit, Subtenant shall within ten (10) business days after written demand therefor, restore the Letter
of Credit to the initial face amount thereof. Provided Subtenant is not otherwise in default under the terms of this Sublease, beyond
any applicable notice and cure periods, the Letter of Credit, or so much thereof as shall not then have been applied by Sublandlord, shall
be returned without payment of interest or other amount for its use, to Subtenant (or, at Sublandlord’s option, to the last assignee,
if any, of Subtenant’s interest hereunder) within thirty (30) days after the expiration of the Sublease Term, and after Subtenant
has vacated and surrendered the Premises as required hereunder. No trust relationship is created herein between Sublandlord and Subtenant
with respect to the Letter of Credit. Subtenant acknowledges that the Letter of Credit is not an advance payment of any kind or a measure
of or limit on Sublandlord’s damages in the event of Subtenant’s default. Any application of the Letter of Credit by Sublandlord
shall be without prejudice to any other right or remedy provided under this Sublease or pursuant to applicable law. The holder of a mortgage
shall not be responsible to Subtenant for the return or application of any the Letter of Credit, whether or not it succeeds to the position
of Sublandlord hereunder, unless the Letter of Credit shall have been received in hand by such holder.

 

8.            Improvements.
Except to the extent permitted under the Overlease without the consent of Overlandlord, Subtenant shall obtain the consent of Overlandlord
to any improvements or alterations Subtenant shall desire to make in the Premises. If the consent of Overlandlord is required with respect
to such improvements or alterations, the consent of Sublandord shall also be required; provided that Sublandlord agrees that it will not
unreasonably withhold, condition or delay its consent to any alterations or improvements consented to by Overlandlord. Notwithstanding
the foregoing, Sublandlord hereby consent to the proposed alterations set forth on Exhibit E (“Subtenant’s Proposed Alterations”)
and the Overlandlord Consent shall provide Overlandlord’s consent to such Subtenant’s Proposed Alterations. Subtenant shall
not be required to remove any such alterations or improvements at the expiration or earlier termination of the Sublease Term unless Sublandlord
or Overlandlord provides Subtenant with written notice of such removal requirement at the time it provides consent to such alterations
or improvements or, in the case of Subtenant’s Proposed Alterations, such removal requirement is specified in Exhibit E or
in the Overlandlord’s Consent. Subtenant’s Proposed Alterations shall be otherwise subject to all requirements of the Lease,
including Section 4.2 thereof.

 

     

     

    

 

9.            Notice.
All notices or communications authorized or required hereunder and rent payment shall be given or sent to Sublandlord at Fresenius Medical
Care, 920 Winter Street, Waltham, MA 02451 (in the case of rent, to the attention of accounts payable) and to Subtenant at Rapid Micro
Biosystems, Inc., Attn: Sean Wirtjes, Chief Financial Officer, 1001 Pawtucket Boulevard, Lowell MA 01854, by certified or registered
mail, return receipt requested, or by a national overnight delivery service which maintains delivery records. Either party may by written
notice to the other designate another address of such party for the purposes of this section. Sublandlord shall promptly give Sublessee
a copy of any notice of default, termination or otherwise affecting the existence or validity of the Sublease or relating to any casualty
or taking, given by Sublandlord or Overlandlord to the other.

 

10.          Broker.
Subtenant represents and warrants to Sublandlord that it has not directly or indirectly dealt with any broker or agent with respect to
the Premises other than CRESA, the “Broker” for purposes of this Sublease.

 

11.          Assignment
and Subletting. Notwithstanding any term or provision of the Overlease to the contrary, Subtenant shall not assign this Sublease,
sublet all or any part of the Premises, encumber this Sublease or allow any third party to use any portion of the Premises without Overlandlord’s
consent and Sublandlord’s consent, which shall not be unreasonably withheld, conditioned or delayed by Sublandlord.

 

12.          Consent.
Whenever any provision of the Overlease requires Overlandlord’s consent, the consent of both Overlandlord and Sublandlord shall
be required.

 

13.          Overlandlord
Termination Right. Sublandlord shall not exercise its termination option under Section 13.39 of the Overlease while this Sublease
shall be in effect.

 

14.          Subtenant
Termination Option. Provided that there exists no default of Subtenant under Section 12.1 of the Overlease beyond applicable
notice and cure periods, at the time Subtenant shall give the termination notice referred to herein, Subtenant shall have the right to
terminate this Sublease as of July 31, 2026 (the “Termination Date”), by giving notice to Sublandlord of exercise of
such termination right on or before the day which is one (1) year prior to the Termination Date, and, if such notice is given, on
the Termination Date this Sublease shall expire just as if such date were the date originally set for expiration of the Sublease Term;
provided that Subtenant shall pay Sublandlord the Early Termination Fee within thirty (30) days after the Termination Date. The “Early
Termination Fee” shall be the sum of (a) $375,063.75 which represents six (6) months’ of the then Base Rent, and
(b) $281,175.96 which represents the unamortized portion, as of the Termination Date, of Sublandlord’s brokerage expenses
and an amount equal to the monthly Fixed Rent from the Commencement Date to the Rent Commencement Date had Fixed Rent been payable during
such period, amortized over the term of this Sublease on a level payment direct reduction basis, with interest at six percent (6%) per
annum, over the period beginning on Rent Commencement Date.

 

15.            Furniture
and Equipment. During the Sublease Term, Subtenant shall have the right to use the furniture and equipment listed in Exhibit B
attached hereto (the “FF&E”). Prior to the Commencement Date, Sublandlord shall remove all of its other property from
the Premises. Subtenant shall pay as additional rent for the FF&E $6,250 per month on the first day of each month during the Sublease
Term. Subtenant shall maintain the FF&E in reasonably good condition, subject to reasonable wear and tear, fire and casualty damage,
and provided Subtenant does not exercise the Subtenant Termination Option herein, shall purchase FF&E at the end of the Sublease Term
for $1.00 and shall thereafter be responsible for the removal and disposal of the FF&E at Subtenant’s sole cost and expense,
as well as any damage related to such removal, as required in the Overlease. Subtenant, at its expense, shall maintain full replacement
cost all risk insurance on the FF&E naming Sublandlord as loss payee.

 

     

     

    

 

16.          Exterior
Storage. Subject to Overlandlord’s and Sublandlord’s consents and approvals, which shall not be unreasonably withheld,
conditioned or delayed, Subtenant may install an exterior storage facility and/or emergency generator, provided such facility complies
with all applicable legal requirements.2

 

17.          Consent;
Non-disturbance. This Sublease is subject to Sublandlord obtaining Overlandlord’s consent hereto, which consent Sublandlord
will request promptly upon the execution hereof and shall be in form and substance reasonably acceptable to Subtenant (the “Overlandlord
Consent”). The Overlandlord Consent shall (a) expressly permit the use set forth in Section 18 below, and (b) provide
Overlandlord’s consent to the Subtenant’s Proposed Alterations. Sublandlord has obtained from the current mortgagee of the
Premises a Subordination, Non-Disturbance and Attornment Agreement, in favor of Subtenant, a copy of which has been provided to Subtenant.
The parties shall cooperate reasonably in connection with the application for Overlandlord’s Consent and furnish such available
documents and information (including, without limitation, information regarding Subtenant’s Proposed Alterations) as Overlandlord
may reasonably require for such purpose. If the Overlandlord’s Consent is not issued within thirty (30) days after the Effective
Date, then either party may elect to cancel this Sublease by giving notice of such cancellation to the other after the end of such thirty
(30) day period. If either party shall give its cancellation notice, this Sublease shall be cancelled, any advance rent and security previously
paid shall be refunded, and neither party shall have any other or further claims arising under this Sublease.

 

18.          Permitted
Use. Notwithstanding anything in the Overlease or this Sublease to the contrary, the Permitted Use under this Sublease shall be general
office and administrative uses, light manufacturing3 and all
uses permitted by applicable zoning laws and uses ancillary thereto.

 

19.          Entire
Agreement/Modification. This Sublease, including the Exhibits, contains all of the agreements of the parties hereto with respect to
any matter covered or mentioned in this Sublease, and no prior agreements or understanding or letter or proposal pertaining to any such
matters shall be effective for any purpose. This Sublease may only be modified by a writing signed by Sublandlord and Subtenant. No provisions
of this Sublease may be amended or added to, whether by conduct, oral or written communication, or otherwise, except by an agreement in
writing signed by the parties hereto or their respective successors-in-interest.

 

20.          Interpretation.
The title and paragraph headings are not a part of this Sublease and shall have no effect upon the construction or interpretation of any
part of this Sublease. Unless stated otherwise, references to paragraphs and subparagraphs are to those in this Sublease. This Sublease
shall be strictly construed neither against Sublandlord nor Subtenant.

 

 

2 To be added to proposed alterations exhibit.

3 Expanded Permitted Use to be approved in Consent.

 

     

     

    

 

Witness the execution hereof under seal as of the
date first above written.

 

	 	SUBLANDLORD
	 	 
	 	NATIONAL MEDICAL CARE, INC., a Delaware corporation
	 	 
	 	 
	 	By /s/[Karen Gledhill]
	 	 
	 	Its SVP General Counsel
	 	 
	 	SUBTENANT:
	 	 
	 	RAPID MICRO BIOSYSTEMS, INC., a Delaware
	 	 
	 	 
	 	By /s/[Sean Wirtjes]
	 	 
	 	 
	 	Its Chief Financial Officer

 

     

     

    

 

Exhibit A

Schedule of Rent

 

     

     

    

 

Exhibit B

Furniture and Equipment

 

     

     

    

 

Exhibit C

Letter of Credit

 

     

     

    

 

Exhibit D

Premises

 

     

     

    

 

Exhibit E

Proposed Alterations

 

     

     

    

 

Exhibit F

OverleaseExhibit 10.14

 

[***] Certain information in this document has been excluded pursuant
to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant
if publicly disclosed.

 

PATENT LICENSE AGREEMENT

 

This Agreement is made and entered into as of the 13th day of May,
2013 (“Effective Date”) by and between Thermo CRS, Ltd., a Canadian corporation and indirect subsidiary of Thermo Fisher
Scientific Inc. (“Licensor”) and Rapid Micro Biosystems Inc., a Delaware corporation (“Licensee”).
Licensor and Licensee may be individually referred to as “Party” and collectively as “Parties.”

 

WHEREAS, Licensor owns and controls U.S. Patent [***], Canadian Patent
[***] and European Patent [***] (the “Licensed Patents”); and

 

WHEREAS, Licensee wishes to obtain a license from Licensor under the
Licensed Patents for the purpose of commercializing Licensed Products as defined below.

 

NOW, THEREFORE, in consideration of the mutual covenants and premised
contained herein, the Parties agree as follows:

 

	1.	DEFINITIONS

 

		1.1	“Affiliate” means any business entity at least 50% owned by a Party, directly or indirectly, any business entity
that owns at least 50% of a Party, directly or indirectly, or any business entity that is at least 50% owned by a business entity that
owns at least 50% of the Party.

 

		1.2	“Change in Control” means a transaction or a series of related transactions: (a) in which one or more parties that
did not previously own or control greater than fifty percent (50%) equity interest in Licensee obtains ownership or control of greater
than fifty percent (50%) equity interest in Licensee; (b) in which Licensee sells all or substantially all of its assets; or (c) a merger
of Licensee with or into an un- Affiliated third party, where Licensee is not the surviving entity. Notwithstanding the foregoing, Change
in Control shall not include (i) any transaction or series of transactions entered into primarily for equity financing purposes so long
as less than 50% of Licensee is owned by entities engaged in the lease or sale of goods or the development of goods for lease or sale
or (ii) any public offering of securities.

 

		1.3	“Field” means [***].

 

		1.4	“Licensed Method” means a method, the practice of which is covered by at least one valid claim of any of the Licensed
Patent Rights in the country of use.

 

		1.5	“Licensed Patent Rights” means the Licensed Patents and any reissues, reexaminations and extensions.

 

		1.6	“Licensed Product” means a product, the manufacture, use or sale of which is covered by at least one valid claim
of any of the Licensed Patent Rights in the country of manufacture, use, or sale.

 

	2.	GRANT

 

		2.1	Licensor hereby grants to Licensee a world-wide, royalty-bearing non-exclusive license under the
                                                                                    Licensed Patent Rights to develop, manufacture, have manufactured for Licensee, use, distribute, promote, sell, have sold through
                                                                                    distributors, import and otherwise commercialize Licensed Products [***] marked with Licensee’s own name and trademark(s) for
                                                                                    use in the Field, and to convey to its direct and indirect customers the right to practice Licensed Methods and use or resell
                                                                                    Licensed Products in the Field.

 

     

     

    

 

[***] Certain information in this document has been excluded pursuant
to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant
if publicly disclosed.

 

		2.2	Except for the rights expressly conveyed to distributors and to direct and indirect customers in Section 2.1, Licensee receives no
right to sublicense under Licensed Patent Rights.

 

		2.3	No right is granted, expressly or by implication, to use Licensed Products outside of the Field or to label Licensed Products with
any name or trademark not owned by Licensee or to sell Licensed Products on a stand-alone basis for use [***].

 

		2.4	Licensee shall mark all Licensed Products with U.S. Patent [***] and other granted patents of the Licensed Patent Rights, as appropriate
in the jurisdiction of use or sale, shall disclose the format for such patent marking to Licensor and shall comply with Licensor’s
reasonable instructions regarding modifications to such format.

 

		2.5	In the event that Licensee obtains patent rights based on an application filed after the Effective Date that cover the manufacture
and/or use [***] covered by the Licensed Patent Rights, Licensee agrees to make available to Licensor a license to such patent rights
under reasonable terms upon Licensor’s request. Notwithstanding the foregoing, Licensee is not obligated to offer a license to Licensor
to patent rights for the use of [***].

 

	3.	FEES AND ROYALTIES

 

		3.1	In partial consideration for rights granted in this Agreement, Licensee shall pay Licensor:

 

		a)	forty thousand dollars ($40,000) within ten business days of the completed execution of this Agreement;

 

		b)	forty thousand dollars ($40,000) within twelve months after the Effective Date; and

 

		c)	forty-five thousand dollars ($45,000) within twenty-four months after the Effective Date.

 

The payments of 3.1(a) and 3.1(b) shall
be non-refundable and non-creditable. The payment of 3.1(c) shall be non-refundable and creditable only against earned royalties with
respect to Licensee sales of Licensed Products during calendar year 2015.

 

		3.2	In partial consideration for the rights granted under this Agreement, Licensee shall pay a royalty of:

 

		a)	[***] for each system containing [***] Licensed Products, except as such amount is adjusted under Sections
3.3 or 3.4, and

 

    2

     

    

 

[***] Certain information in this document has been excluded pursuant
to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant
if publicly disclosed.

 

		b)	[***] per Licensed Product for each system containing [***] Licensed Products other than [***], except
as such amount is adjusted under Sections 3.3 or 3.4.

 

		3.3	It is understood that any legal challenge of the subject patents, through USPTO, EPO or other legal proceedings would be costly for
the Licensor, and therefore it is agreed that any challenge initiated or facilitated by the Licensee would increase the cost of the license.
In the event that Licensee challenges or facilitates a challenge to the validity of any of the Licensed Patent Rights, the above fees
shall be increased from [***] to [***] and from [***] to [***], for the current quarter and all subsequent quarters.

 

		3.4	If Licensee is obligated to pay a royalty to a third party on [***] for which a royalty is due to Licensor, then Licensee may reduce
the amount payable to Licensor by half of what it pays to the third party; provided that the amount payable to Licensor on each system
shall not be reduced under this clause by more than [***] (e.g., from [***] to [***]).

 

		3.5	Licensee shall transmit reports of licensed products sold to Licensor (to Licensor’s designated e-mail address with a confirmation
copy by regular mail) within [***] days after the end of each calendar quarter (commencing with the first calendar quarter in which a
Licensed Product under the license has been sold). Each report shall identify the numbers of units sold (by model number) and calculate
the royalties due (after reflecting the amount creditable in 3.1c for reports on sales in a quarter of 2015). The mailed confirmation
copy shall be accompanied by payment.

 

	4.	TERM AND TERMINATION

 

		4.1	The Agreement shall go into effect as of the Effective Date, provided that the payment of Section 3.1a is made, and shall remain in
effect until the last to expire of the Licensed Patent Rights.

 

		4.2	Licensee may terminate at any time, with [***] days prior written notice to Licensor.

 

		4.3	Licensor may terminate for cause, in the event that Licensee is in breach of any obligation under the agreement, after notice of breach
with: a) [***] days’ notice (unless Licensee cures such notified breach within the [***] day period); and b) effective immediately
in the event that Licensee is insolvent, files for bankruptcy or receivership under any applicable law. If the notified breach under (a)
is failure to report and pay royalties when due, the notice and cure period shall be shortened to [***] days for the second breach and
to no cure period for any subsequent breach.

 

		4.4	Licensor shall also have the right to terminate in the event Licensee challenges or facilitates the challenge of any of the patents
or patent applications under Licensed Patent Rights.

 

		4.5	Licensor shall have the right to terminate this Agreement with [***] months prior written notice to Licensee if there is a
                                                                  Change in Control in Licensee and Licensee has failed to obtain Licensor’s written consent either prior to its effective date or, if such prior approval is impracticable, within
[***] days after its effective date. Licensor shall not unreasonably withhold approval of a Change in Control. Licensor shall have a period
to exercise this right of up to [***] months from the date on which Licensor is notified of the Change in Control.

 

    3

     

    

 

[***] Certain information in this document has been excluded pursuant
to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant
if publicly disclosed.

 

	5.	GENERAL PROVISIONS

 

		5.1	This Agreement shall be governed by the laws of Massachusetts. The provisions of the United Nations Convention on Contracts for the
International Sale of Goods will not apply to this Agreement.

 

		5.2	This Agreement constitutes the entire and only agreement between the Parties with respect to Licensed Patent Rights and Licensed Products;
and all other prior negotiations, representations, agreements, and understandings are superseded hereby. No agreement altering or supplementing
the terms hereof may be made except by a written document signed by both Parties.

 

		5.3	This Agreement will not be assigned nor sublicensed by Licensee without Licensor’s prior written consent, and any purported
assignment or sublicense made without such prior written consent shall be void.

 

		5.4	Notices under this Agreement shall be given in writing, either certified mail or express delivery, to the following addresses or such
other as may be provided from time to time under the terms of this notice provision:

 

	 	If to Licensor:	THERMO CRS, LIMITED
	 	 	5344 John Lucas Drive
	 	 	Burlington, ON L7L 6A6
	 	 	Attn: Site Leader
	 	 	 
	 	With a copy to:	Legal Department
	 	 	Thermo Fisher Scientific
	 	 	81 Wyman Street
	 	 	Waltham, MA 02454-9046
	 	 	 
	 	If to Licensee:	RAPID MICRO BIOSYSTEMS INC.
	 	 	One Oak Park Drive
	 	 	Bedford, MA 01730

 

		5.5	Licensor and its Affiliates DISCLAIM ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. IN NO
EVENT WILL LICENSOR OR ITS AFFILIATES BE LIABLE HEREUNDER TO THE LICENSEE, ITS AFFILIATES, OR ANY OTHER PERSON OR ENTITY FOR SPECIAL,
INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR OTHER INDIRECT DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS OR LOSS OF USE DAMAGES)
INCURRED BY THE OTHER PARTY OR PERSON AND ARISING FROM ANY MANUFACTURE, USE, OR SALE OF LICENSED PRODUCTS EVEN IF SUCH OTHER PARTY OR
PERSON HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSSES.

 

    4

     

    

 

[***] Certain information in this document has been excluded pursuant
to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant
if publicly disclosed.

 

		5.6	Licensee shall indemnify, defend and hold harmless Licensor with respect to any third party claim against Licensor arising out of
Licensee’s manufacture, use or sale of Licensed Products.

 

		5.7	Headings are included herein for convenience only and will not be used to construe this Agreement.

 

		5.8	If any part of this Agreement is for any reason found to be unenforceable, all other parts will remain enforceable to the fullest
extent possible.

 

		5.9	This Agreement may be signed in two counterparts transmitted between the Parties as electronic documents, both of which together shall
constitute one and the same Agreement, binding on the Parties as if each had signed the same document.

 

IN WITNESS WHEREOF, Parties
hereto have caused their duly authorized representatives to execute this Agreement.

 

	 	THERMO CRS, LTD	 	RAPID MICRO BIOSYSTEMS, INC.
	 	 	 	 
	 	By: 	/s/ Hansjoerg Haas	 	By: 	/s/ Stephen H. Delity
	 	Name: 	Hansjoerg Haas	 	Name: 	Stephen H. Delity
	 	Title: 	Productline Dir.	 	Title: 	President and CEO
	 	Date: 	May 13, 2013	 	Date: 	June 10, 2013

 

    5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]